Period:
Draw Mode:
| Volume | 714,418 |
|
|||||
| News | - | ||||||
| Day High | 43.075 | Low High |
|||||
| Day Low | 41.94 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ionis Pharmaceuticals Inc | IONS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.05 | -0.12% | 42.66 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 42.66 | 41.94 | 43.075 | 42.66 | 42.71 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 10,953 | 714,418 | $ 42.61 | $ 30,440,814 | - | 32.69 - 47.74 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:50:40 | 4 | $ 41.95 | USD |
Ionis Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 6.11B | 143.33M | - | 587.37M | -269.72M | -1.88 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Ionis Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IONS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 42.83 | 43.4613 | 41.57 | 42.73 | 793,769 | -0.17 | -0.4% |
| 1 Month | 40.38 | 44.505 | 39.08 | 41.96 | 826,971 | 2.28 | 5.65% |
| 3 Months | 41.14 | 44.505 | 38.26 | 41.01 | 896,604 | 1.52 | 3.69% |
| 6 Months | 34.14 | 44.505 | 33.32 | 39.72 | 1,065,071 | 8.52 | 24.96% |
| 1 Year | 43.07 | 47.74 | 32.69 | 39.93 | 1,034,530 | -0.41 | -0.95% |
| 3 Years | 48.60 | 64.37 | 25.04 | 40.32 | 1,123,661 | -5.94 | -12.22% |
| 5 Years | 50.52 | 88.7075 | 25.04 | 47.79 | 1,073,727 | -7.86 | -15.56% |
Ionis Pharmaceuticals Description
| Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). |